The Footnote

The Toenail That Exposes Medicare

Author attribution not recorded

Two identical surgical trays side-by-side, one illuminated and one in shadow, representing funding bias.

The GP can bill it. The podiatrist cannot. That is not an accident. It is the system.

Patients regularly sit in my treatment chair with an ingrown toenail and tell me they are going to “see a doctor” about it.

I have to remind them that they already are.

I am a doctor of podiatric medicine. My clinical practice is devoted to foot and ankle medicine. I assess the nail, the surrounding tissue, the circulation, neurological status, footwear, toe structure, mechanical pressure, infection risk and capacity to heal.

But when the patient says “doctor,” they mean a GP.

They do not necessarily mean the practitioner with the greatest expertise in the condition sitting directly in front of them. They mean the practitioner whom Medicare, language and professional culture have placed at the centre of Australian healthcare.

The GP is the doctor.

The podiatrist is “allied health.”

Allied to whom?

An ingrown toenail may seem an absurdly small place to begin an argument about healthcare hierarchy. That is precisely why it is so useful.

There is nowhere for the hierarchy to hide.

This is not a rare disease requiring a brilliant generalist to synthesise twenty competing diagnoses. It is not a complex multisystem presentation that can only be understood by the one practitioner who “sees the whole patient.”

It is a painful toenail.

Podiatrists assess and treat them every working day.

Yet Medicare has decided that a partial nail avulsion becomes publicly valuable when performed by a GP and financially invisible when performed by a podiatrist.

That small fact exposes the whole system.

The fact Medicare cannot explain

MBS item 47916 is a specific surgical item for partial resection of an ingrowing toenail, including phenolisation.

Its current schedule fee is $101.95. The out-of-hospital Medicare benefit is $86.70.

An eligible GP can bill it when the service meets the item requirements.

A podiatrist cannot.

Not a smaller rebate.

Not a reduced benefit.

Nothing.

The rebate is not attached to the patient.

It is not attached to the toenail.

It is not even truly attached to the procedure.

It is attached to the professional category of the person performing it.

A GP can assess the toe, administer local anaesthetic, remove part of the nail, apply phenol to destroy the corresponding section of matrix and claim item 47916.

A podiatrist can assess the same toe, administer the same local anaesthetic, perform the same partial nail avulsion, use the same matrix-ablation technique, apply the dressing and supervise healing.

The podiatrist cannot claim item 47916.

Medicare has created a rebate for toenail surgery and excluded the profession whose clinical scope is concentrated on foot and ankle pathology from using it.

That is not an incidental gap in the schedule.

It is the hierarchy written down.

Medicare does not fund the best practitioner

The usual defence is that GPs are broadly trained and legally permitted to perform nail surgery.

True.

Also irrelevant.

Legal permission is the minimum threshold for doing something without committing an offence. It is not a quality-assurance system.

It does not tell us how often the practitioner performs the procedure.

It does not tell us whether they understand nail anatomy.

It does not tell us whether they can perform a proper digital nerve block.

It does not tell us whether they distinguish mechanical inflammation from infection.

It does not tell us whether they offer conservative care before permanent ablation.

It does not tell us whether they obtain meaningful consent, wait for anaesthesia or review the wound afterwards.

It tells us only that their professional scope is broad enough to include the act.

That is a very low bar upon which to construct a public funding system.

A GP may be an excellent nail surgeon. A podiatrist may be a poor one. The answer is not to assume the opposite hierarchy and hand podiatrists a blank cheque.

The answer is to stop pretending that provider category is a substitute for competence.

Public funding should follow appropriate scope, demonstrated capability and accountable care.

Instead, Medicare sees the provider number and releases the rebate.

The item rewards the intervention

There is another problem hidden inside the wording of item 47916.

The item is not for assessing an ingrown toenail.

It is not for skilled decompression.

It is not for removing a distal spicule before it becomes a surgical problem.

It is not for managing footwear pressure, teaching appropriate nail care or preventing recurrence.

It is specifically for partial resection including phenolisation.

Phenolisation is permanent chemical destruction of part of the nail matrix. The purpose is to prevent that portion of nail from growing again. Although it has a high fail rate.

Medicare therefore has a procedure-specific item for destroying the matrix.

It has no direct podiatry item for the clinical judgement that might establish that the matrix does not need to be destroyed.

This matters because many painful nails do not initially require permanent ablation.

They require a competent examination.

They require identification and complete removal of the offending distal nail corner or spicule. They require decompression of the sulcus without manufacturing another sharp edge. They may require management of hyperkeratosis or hypergranulation tissue.

They require advice about footwear, pressure, trauma and nail-cutting behaviour.

They require review.

Even the RACGP’s own guidance says that ingrowing nails should ideally be managed conservatively in the first instance. It describes careful trimming of the offending distal nail corner, specifically recommends podiatry referral where appropriate, and warns against leaving sharp projections behind.

This is ordinary podiatric medicine.

It is also invisible to Medicare.

The intervention has an item number.

Restraint does not.

The permanent procedure is subsidised.

The expertise that may prevent it is left entirely to the private market.

Medicare pays for the phenol.

The patient pays for the judgement.

When permanent correction is necessary

Some nails do require permanent treatment.

Recurrent penetration, pathological nail shape, hypertrophic folds and failure of appropriate conservative management may justify definitive correction.

But the procedure should follow the pathology.

The pathology should not be reverse-engineered to fit the available item.

In properly selected recurrent or structurally driven cases, a formal nail wedge resection may be preferable to reflexively applying phenol to every painful sulcus. It allows direct removal of the pathological nail segment, affected nail fold and relevant matrix tissue.

Medicare has an item for that too.

Item 47915 covers wedge resection meeting a detailed descriptor that includes removal of the nail segment and ungual fold, together with excision and partial ablation of the germinal matrix and part of the nail bed. Its current schedule fee is $202.90 and its out-of-hospital benefit is $172.50.

Again, an eligible GP or other eligible practitioner within Medicare’s recognised medical-practitioner category can claim it when the descriptor is satisfied.

A podiatrist cannot.

The issue is not whether every podiatrist should perform every nail operation.

The issue is that Medicare has already decided which profession counts before asking who is trained, experienced or best placed to do it.

The consequences of confusing status with competence

This funding arrangement might be merely insulting if it produced reliably excellent care.

It does not.

Podiatrists routinely see patients after nail treatment has failed.

I see retained spicules still embedded in the sulcus after an attempted avulsion.

I see nails torn rather than properly divided and removed.

I see hypergranulation treated as infection while the mechanical source remains untouched.

I see patients who have received repeated antibiotics without anyone removing the piece of nail penetrating the tissue.

I see children who panic before I have even touched them because a previous procedure taught them that local anaesthetic cannot be trusted.

These are clinical observations and patient accounts, not a national comparative trial of GP and podiatry outcomes.

That limitation should be stated.

It should not be used as a demand that clinicians ignore a recurring pattern until someone funds a ten-year epidemiological study into traumatised toenails.

The anecdotes are not proof that every GP performs poor nail surgery.

They are proof that Medicare’s preferred provider category is not a quality guarantee.

That is enough to collapse the logic of the current system.

A needle in a toe is not a ring block

One of the most disturbing recurring accounts involves the anaesthetic.

Patients describe the needle being inserted through the apex of the toe or directly beside the inflamed nail fold. Local anaesthetic is injected into the most painful tissue on the digit. The practitioner then starts cutting or pulling almost immediately.

The needle entered the toe.

Therefore, everyone behaves as though a digital ring block occurred.

It did not.

A digital block is regional anaesthesia. The local anaesthetic is deposited proximally to interrupt the nerves supplying the toe.

The RACGP’s own guidance describes a digital ring block proximal to the area of erythema. Perth Children’s Hospital guidance says a digital nerve block should be allowed several minutes—up to ten—to become effective. If sensation remains, the injections may need to be repeated, followed by another period of waiting.

An apical stab into inflamed distal tissue is not a stylistic variation on the same technique.

It suggests the practitioner may not understand what a ring block is.

Anaesthetic injected into inflamed tissue is exquisitely painful. It may fail to interrupt the digital nerves adequately. The practitioner then begins the procedure while the patient can still feel it, interprets the reaction as anxiety or poor tolerance and injects more anaesthetic into an increasingly traumatised field.

This is the performance of anaesthesia without the achievement of anaesthesia.

Some patients report being told that they should feel pressure but not pain while experiencing unmistakable pain.

Some parents describe children being restrained while the attempt continued.

Some patients report that the procedure was commenced before they had meaningfully agreed to it. The practitioner told them what was about to happen and proceeded.

That is not informed consent.

It is notification.

The professional codes governing registered practitioners require informed consent before treatment except in an emergency.

The patient later arrives in podiatry saying that local anaesthetic does not work on them.

Usually, the anaesthetic was not the problem.

The problem was that nobody performed the block correctly, waited for it to work or tested the toe before beginning.

The failed procedure has not simply left the nail untreated.

It has made the next treatment harder.

The podiatrist now has to treat the toe and persuade the patient that healthcare is not supposed to feel like an assault.

That takes time.

Antibiotics cannot remove a nail spike

An ingrowing nail is fundamentally a mechanical problem.

A nail edge or spicule is pressing into, irritating or penetrating the surrounding tissue. Nail shape, trauma, cutting technique, footwear pressure and toe anatomy may all contribute.

The toe may be red.

It may be swollen.

It may be painful and discharging.

That does not automatically mean the primary pathology is a bacterial infection requiring systemic antibiotics.

Antibiotics cannot remove a nail spike.

They cannot decompress the sulcus.

They cannot widen a shoe.

They cannot correct a nail repeatedly cut down the sides.

They cannot compensate for failing to examine the toe.

Yet podiatrists repeatedly inherit patients who have completed one or more courses of antibiotics while the nail remains embedded in the tissue.

The prescription substitutes for source control.

RACGP guidance itself says oral antibiotics are usually unnecessary once the offending nail section and hypergranulation tissue have been removed.

That does not mean antibiotics are never required.

It means redness is not a diagnosis.

It means inflammation is not automatically infection.

It means antimicrobial stewardship involves more than choosing the correct drug. It requires recognising when the drug is not the treatment.

The patient takes the tablets.

The toe remains mechanically impaled.

The consultation has been billed.

The price of doing it properly

As the results of my informal LinkedIn survey show, fees for a single-sided partial nail avulsion under local anaesthetic vary considerably.

Reported fees ranged from the low $200s to $500 or more, with most responses falling within the $300–$499 range. The average reported fee was $340.

It was a LinkedIn survey.

It was not a random sample, a government fee audit or a peer-reviewed economic study.

That does not make the responses useless. It means they should be used for what they are: a snapshot of what podiatry clinics report charging to make this service viable.

For the same procedure performed by a podiatrist, the ordinary patient receives no procedure-specific Medicare rebate.

A GP clinic could also charge $340 for a service satisfying the requirements of MBS item 47916. Medicare would contribute $86.70, reducing the patient’s out-of-pocket cost to $253.30.

Both clinics receive $340.

The GP patient pays $253.30.

The podiatry patient pays $340.

The podiatry pathway has not suddenly become more expensive to provide.

Medicare has simply paid part of one bill while contributing nothing to the other.

The price advantage is not natural.

It is manufactured.

The $340 does not go into the podiatrist’s pocket

A PNA fee is not a personal prize for pulling out a strip of nail.

It is gross clinic revenue.

It must fund the clinician’s time, reception, administration, documentation, the treatment room, sterile instruments, sterilisation, local anaesthetic, dressings, consumables, clinical waste, insurance, equipment, wages and rent.

It must fund the time required to do the procedure safely.

A nervous child may need explanation, patience and trust.

A needle-phobic adult may need coaching.

A patient traumatised by a previous attempt may need every step explained more than once.

They may need pauses.

They may need to be shown that the toe is genuinely numb before they allow the procedure to continue.

The block must be performed properly.

Then the clinician waits.

Then the toe is tested.

If sensation remains, more anaesthetic may be required.

Then everyone waits again.

This is not inefficient care.

It is care.

A private podiatry clinic could not charge the $101.95 MBS schedule fee, allocate the necessary time, provide the materials, maintain the equipment, manage sterilisation, deliver follow-up and remain viable.

The $86.70 Medicare benefit would cover even less.

The MBS fee only looks sufficient when it is treated as though the GP clinic exists inside a vacuum.

It does not.

The GP clinic is already inside the funding system

General practice operates within a substantial Commonwealth support structure.

The Practice Incentives Program contains seven incentives across three payment streams. The Workforce Incentive Program provides eligible practices with quarterly payments to engage health professionals and includes rural loadings of up to 60%.

Not every general practice receives every payment.

Those payments cannot simply be added to the value of every PNA.

That is not the argument.

The argument is that general practice operates inside a publicly supported ecosystem.

Independent podiatry does not.

There is no Podiatry Practice Incentives Program.

There is no directly accessible podiatry PNA item.

There is no equivalent quarterly Commonwealth support for the independent podiatry clinic carrying the staff, equipment and infrastructure required to provide the service.

The irony is particularly revealing under workforce incentives.

The system may help fund a general practice to engage an “allied-health” practitioner.

The podiatrist’s labour becomes worthy of public support when incorporated into a GP-centred business.

The same podiatrist working inside a podiatry-led clinic receives no comparable support.

Medicare will fund podiatry beneath general practice.

It will not fund podiatry beside it.

“But podiatrists already have Medicare”

This is the next sleight of hand.

Podiatry appears in the MBS, therefore podiatry is supposedly funded.

Item 10962 is the usual exhibit.

It is a generic podiatry attendance for an eligible patient with chronic and complex care needs being managed under a qualifying plan. It requires a referral, must last at least 20 minutes and consumes one of a maximum of five shared MBS-supported health services in the calendar year. Its current schedule fee is $74.55 and benefit is $63.40.

It is not a nail-surgery item.

It is not directly accessible to an ordinary self-referred patient.

It does not recognise the procedure, anaesthetic, equipment, sterilisation or postoperative care.

A podiatrist cannot turn item 10962 into item 47916 by performing a PNA during the appointment.

Podiatrists have no generally accessible, procedure-specific MBS item for nail decompression, partial nail avulsion, phenol matrixectomy or wedge resection.

Not one.

The GP has the procedure code.

The podiatrist has a restricted attendance unlocked through a GP-managed pathway.

The GP opens the gate.

The so-called allied practitioner waits on the other side.

Allied to whom?

The term “allied health” is often defended as a harmless administrative category.

It is not harmless when it describes the power relationship so accurately.

These are autonomous, university-qualified practitioners who assess, diagnose and treat disease within defined scopes of practice.

Yet the title places them in orbit around a presumed centre.

They are allied with the real healthcare professionals.

They assist the doctors.

They receive the referral.

They report back.

They can identify the pathology, perform the treatment, manage the complication and recognise when escalation is required.

But another profession’s item number makes the care economically legitimate.

The patient learns the hierarchy quickly.

The GP is subsidised.

The podiatrist is private.

The GP provides the plan.

The podiatrist receives the plan.

The GP can bill the operation.

The podiatrist cannot.

Then the patient sits in front of the doctor of podiatric medicine and says they intend to see a doctor.

Language follows money.

Status follows funding.

Then the funding is defended by pointing to the status it created.

The strongest defence of the GP-centred model

The serious defence is not that every GP is better at toenail surgery.

It is that GPs manage the whole patient.

They know the diabetes, vascular disease, immunosuppression, medications, allergies and broader diagnostic context.

That breadth is valuable.

It is not ownership.

Podiatrists are trained to assess the systemic, vascular, neurological, dermatological and mechanical factors affecting the lower limb. We recognise when impaired perfusion, neuropathy, infection or systemic disease changes the risk. We recognise when the patient needs a GP, vascular specialist, emergency department or another practitioner.

That is how autonomous professions work.

They practise within scope and escalate beyond it.

A GP’s broader scope does not establish superior competence in every narrow procedure contained somewhere within that scope.

Breadth is not depth.

Knowing more unrelated things does not necessarily make someone better at treating the toe.

The system should value both.

Instead, it converts breadth into ownership and depth into assistance.

The toenail is not an exception

The same logic appears throughout Australian primary care.

A practitioner may already have assessed the patient, formed a diagnosis and identified the need for escalation.

Medicare may still require the patient to return to a GP to obtain the administratively acceptable plan or referral.

The GP becomes a compulsory tollbooth.

This wastes appointments.

It delays care.

It adds cost.

It tells the patient that the first practitioner’s judgement does not count until approved by the recognised profession.

The federal Scope of Practice Review identified funding and payment policy among the barriers preventing health practitioners from working to their full scope. The government is also reviewing direct referrals from allied-health and other primary-care practitioners to non-GP specialists, with that process expected to take approximately 12 to 18 months.

The problem has been reviewed.

It has been documented.

It has been placed into committees.

The hierarchy remains intact.

The toenail is not an anomaly.

It is the system in miniature.

Fund the care, not the rank

The reform required is not complicated.

Create direct, procedure-specific MBS items that appropriately qualified podiatrists can claim.

Attach them to competence and clinical governance rather than professional mythology.

Require appropriate case selection.

Require informed consent.

Require adequate anaesthesia.

Require postoperative care.

Measure recurrence and complications.

Reward conservative management when conservative management prevents unnecessary surgery.

Apply those standards to everyone.

A GP who performs PNAs regularly, competently and accountably should be funded.

A podiatrist who does the same should be funded.

A poor practitioner should not be protected by their title, whichever profession they belong to.

That is not professional empire-building.

It is the opposite.

It is asking Medicare to stop funding professional rank and start funding healthcare.

Whose care counts?

An ingrown toenail should not expose an entire health system.

But it does.

An eligible GP can claim item 47916.

A podiatrist cannot.

The GP can receive public funding to permanently destroy part of the nail matrix.

The podiatrist receives nothing for determining that the matrix may not need to be destroyed.

The GP clinic operates inside a publicly supported system.

The independent podiatry clinic must recover the entire cost directly from the patient.

The proper ring block and the apical stab look identical in Medicare data.

The careful wait and the immediate traumatic avulsion produce the same item number.

The complete procedure and the retained spicule produce the same item number.

The necessary operation and the unnecessary ablation produce the same item number.

Medicare does not know who performed the procedure well.

It only knows who was allowed to bill it.

That is the scandal.

A rational health system would direct the patient towards the practitioner most likely to provide the right care.

Medicare directs the patient towards the profession that owns the item number.

The problem was never simply that podiatrists sometimes have to repair failed GP procedures.

The problem is that the system financially privileges the GP procedure before anyone has asked who is best placed to perform it.

The toenail is merely where the hierarchy becomes too ridiculous to disguise.

Medicare does not simply fund healthcare.

It funds an order of importance.

And everyone placed beneath the GP is still expected to call that collaboration.